Challenges in targeting residual risk in diabetic patients, post ACS
Video navigation menu
- Categories of residual risk in secondary prevention 2:04
- Causes of inflammatory residual risk and treatment options 4:07
- Novel antiatherosclerotic therapies 6:35
- Epigenetic modulation of gene transcription 8:02
- BET inhibition may affect many mediators and thereby CV outcomes 11:35
This lecture by prof. Peter Libby was part of an accredited symposium "Epigenetics: A new pathway to tackle residual risk?" held during ESC 2019 in Paris, France.
Peter Libby, MD is a cardiologist and a cardiovascular medicine specialist at Brigham and Women’s Hospital (Boston, MA, USA) and the Mallinckrodt Professor of Medicine at Harvard Medical School (Boston, MA, USA).
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: